



Correction

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. *Int. J. Mol. Sci.* 2017, 18, 401

Anna M. Serwotka-Suszczak ¹, Alicja M. Sochaj-Gregorczyk ¹, Jerzy Pieczykolan ^{2,†} ,
Daniel Krowarsch ³ , Filip Jelen ⁴ and Jacek Otlewski ^{1,*}

¹ Department of Protein Engineering, Faculty of Biotechnology, University of Wrocław, 50-137 Wrocław, Poland; aniaserwotka@wp.pl (A.M.S.-S.); alicja.sochaj-gregorczyk@uj.edu.pl (A.M.S.-G.)

² Drug Discovery Department, Adamed Group, 05-152 Czosnow, Poland;
jerzy.pieczykolan@celonpharma.com

³ Department of Protein Biotechnology, Faculty of Biotechnology, University of Wrocław, 50-137 Wrocław, Poland; daniel.krowarsch@uwr.edu.pl

⁴ Research and Development Department, Pure Biologics Ltd., 54-427 Wrocław, Poland;
filip@purebiologics.com

* Correspondence: jacek.otlewski@uwr.edu.pl; Tel.: +48-713-752-824

† Current address: Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland.

Received: 8 November 2018; Accepted: 10 November 2018; Published: 20 November 2018



It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version.

We would like to change the Dr. Jerzy Pieczykolan' affiliation on Page 1 of paper [1] from:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland;
jerzy.pieczykolan@celonpharma.com.

to the correct version, as follows:
Drug Discovery Department, Adamed Group, Czosnow 05-152, Poland;
jerzy.pieczykolan@adamed.com.pl.

And add the following affiliation as the current address of Dr. Jerzy Pieczykolan:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland;
jerzy.pieczykolan@celonpharma.com.

This correction does not cause any changes to results and conclusions in the original published paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Serwotka-Suszczak, A.M.; Sochaj-Gregorczyk, A.M.; Pieczykolan, J.; Krowarsch, D.; Jelen, F.; Otlewski, J. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. *Int. J. Mol. Sci.* **2017**, *18*, 401. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).